$PDSB 2024 Catalysts

- Initiate pivotal study in HNSCC: PDS01ADC + Versamune® HPV + pembrolizumab Triple Combo - 2024

- Update on regulatory confirmation of potentially registrational study - Q3-2024

- File IND for Versamune MUC1 Triple Combo Ph 1/2 study in t/m colorectal…

#dcvax $nwbo #gbm

Another Merck Phase 3 failure -
- KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab)

'KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of…

Health Stocks News $MRK another poor #Keynote #Keytruda trial.
Large synergistic effect anti-PD1 #pembrolizumab + ITK inhibitor $CRVS #soquelitinib increases murine survival from 25% to 90%!
ITKi reverses T-cell exhaustion

$CRVS upcoming solid tumor mono/combo! 2024/25

twitter.com/ConradEnge9805…

olmadığından alamıyoruz bu ilacın temini için sizlerden yardım istiyorum.
İlaç İsmi: KEYTRUDA Pembrolizumab
#ttik #sgk #titck #Cumhurbaşkanlığı #akilciilac #cimer TİTCK Akılcı İlaç Kullanımı

#ScienceLink #Pembrolizumab #KEYNOTE811
shorturl.at/frFRY

🔎 Following the KEYNOTE-811 trial, Merck announced that #pembrolizumab with #trastuzumab and chemotherapy may benefit patients with HER2-positive, locally advanced, unresectable or metastatic gastric or GEJ adenocarcinoma.

👉 Learn more: buff.ly/3wqH5YA

#ThinkSabio #Trendingstock $SPX $SPY $XBI $QQQ $IWM #Markets

$CGEM: $28.75
Live Cash: $382.59M

$19.27 to $29.35 Diff :$10.08
* Consistently going up since 3 weeks with 62% Gain

Upcoming catalyst:
Drug: CLN-619 - (MICA) monotherapy and in combination with pembrolizumab
Date:…

Treatment with eftilagimod alpha plus standard-of-care radiotherapy and pembrolizumab was shown to be well tolerated and led to encouraging initial efficacy data in patients with soft tissue sarcoma. #oncology #sarcoma onclive.com/view/eftilagim…

Why pembrolizumab does not work along with cisplatin based CTRT in head neck cancer ( keynote 412 ) But same pembrolizumab works in cervical cancer with CTRT ( Keynote A18 ) . Perspective by Dr Voortman for head neck cancer part in The Lancet Oncology What can be reasons? Different…

Pembrolizumab จะไปสุดที่ตรงไหน

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent $MRK healthstockshub.com/news/nyse/mrk/…

The long and winding road to biomarkers for immunotherapy🏔️

A comprehensive analysis led by Laurence Buisseret of samples from pts with TNBC treated with pembrolizumab highlights the huge heterogeneity among TNBCs

Now out in ESMO Open ⬇️

OncoAlert

authors.elsevier.com/sd/article/S20…

📢 Supervivencia global con pembrolizumab adyuvante en el #carcinoma de células renales.
▶️El #pembrolizumab adyuvante se asoció con una mejora clínicamente significativa en la supervivencia general, comparado con placebo, entre las🤼 mayor riesgo de recurrencia.‼️…

【呼吸器内科】
ASCO2023_肺がんまとめ

主要演題テーマ
・術前におけるニボルマブの根治手術有無による有効性の違いは？
・術前におけるPembrolizumab＋Ramucirumabの有効性と安全性は？
・術前におけるオシメルチニ

▼続きはAntaa Slideで
slide.antaa.jp/article/view/6…

Check an article on patients who completed two years of #pembrolizumab for advanced NSCLC, highlighting high rates of KRAS mutation & PD-L1 expression, and a subset with brain metastases and treated oligoprogression.

Full article: bit.ly/3Qz1FNa

Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression in cohort B of the phase 2b KEYNOTE-PNC-34/TACTI-003 trial. #hncsm #oncology onclive.com/view/eftilagim…

We need to change the paradigm in LA-HNSCC. Adding anti-PD1/PDL1 concurrently or adjuvantly has not worked. I think the solution will come with better biomarkers, changing radiation dosing, and rationally applied therapy sequencing. thelancet.com/journals/lanon…

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Clinical Cancer Research #MedEd #MedX #senology #oncology #breast #cancer

doi.org/10.1158/1078-0…

Thank you to Dr. Penny Bradbury Princess Margaret Cancer Centre for presenting the phase III IND227 results - Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma at the #CCTG2024 plenary.